Yoshifumi Soejima

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2014 · 261 citations · Full text

Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN8601) in patients with advanced malignancy.

Kenji Eguchi, Satoru Sasaki, Tomohide Tamura et al. · PubMed · 1989 · 52 citations

Immunology, Pathology, Pharmacotherapy +17

Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Yoshio Okano, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2013 · 39 citations

Advanced Nsclc, Medicine, Cancer Management +13

Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe Neutropenia

Yoichi Nakamura, Hiroshi Soda, Mikio Oka et al. · Journal of Thoracic Oncology · 2010 · 33 citations · Full text

Phase Ii Trial, Medicine, Metronomic Therapy +7

Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer

Minoru Fukuda, Mikio Oka, Hiroshi Soda et al. · Cancer Chemotherapy and Pharmacology · 2004 · 27 citations

Non-small-cell Lung Cancer, Medicine, Pharmacology +6